crizanlizumab
Showing 1 - 8 of 8
Sickle Cell Disease Trial (Crizanlizumab, control)
Not yet recruiting
- Sickle Cell Disease
- Crizanlizumab
- control
- (no location specified)
Jul 19, 2022
RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy Trial in Saint Louis, Philadelphia (Crizanlizumab)
Active, not recruiting
- RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy
- Crizanlizumab
-
Saint Louis, Missouri
- +1 more
Jan 27, 2022
COVID-19 Trial in Baltimore (Crizanlizumab, 0.9% saline)
Completed
- COVID-19
- Crizanlizumab
- 0.9% saline
-
Baltimore, MarylandJohns Hopkins Hospital
Nov 3, 2021
Sickle Cell Disease (SCD) Trial in India (crizanlizumab)
Recruiting
- Sickle Cell Disease (SCD)
- crizanlizumab
-
Hyderabad, Andhra Pradesh, India
- +7 more
Mar 31, 2022
Priapism Trial in United States (crizanlizumab)
Recruiting
- Priapism
- crizanlizumab
-
Birmingham, Alabama
- +18 more
Jan 17, 2023
Sickle Cell Disease Trial in Worldwide (Crizanlizumab)
Recruiting
- Sickle Cell Disease
- Crizanlizumab
-
Birmingham, Alabama
- +19 more
Jun 20, 2022
Sickle Cell Disease (SCD) Trial in United States (crizanlizumab)
Active, not recruiting
- Sickle Cell Disease (SCD)
- crizanlizumab
-
Orange City, Florida
- +11 more
Apr 25, 2022
Myelofibrosis Trial in Worldwide (Ruxolitinib, Siremadlin, Crizanlizumab)
Suspended
- Myelofibrosis
- Ruxolitinib
- +5 more
-
Adelaide, South Australia, Australia
- +37 more
Aug 18, 2022